DCM
CMTA

DAFNA Capital Management’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

DAFNA Capital Management’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-105,000
Closed -$1.59M – 88
2018
Q1 		$1.59M Buy
105,000
+45,000
+75% +$732K 0.77% 38
2017
Q4 		$1.14M Hold
60,000
– – 0.61% 48
2017
Q3 		$1.01M Buy
+60,000
New +$981K 0.63% 47

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DAFNA Capital Management's CMTA Position: Q2 2018 in Review

DAFNA Capital Management sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2018, closing a stake of 105,000 shares — an estimated $1.59M sold.

DAFNA Capital Management first reported a position in CMTA in Q3 2017 and held it in 3 quarters. The position peaked at $1.59M in Q1 2018. 29 funds tracked by Wall St. Rank hold CMTA as of Q2 2018.

  • DAFNA Capital Management reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2018 after selling out during the quarter.
  • DAFNA Capital Management sold 105,000 Clementia Pharmaceuticals Inc. shares in Q2 2018, an estimated $1.59M.
  • DAFNA Capital Management first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 3 quarters.
  • DAFNA Capital Management's Clementia Pharmaceuticals Inc. position peaked at $1.59M in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2018.

Based on DAFNA Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.